CN Patent

CN105687132B — 一种坦西莫司注射用浓溶液及其制备方法

Assigned to Lunan Better Pharmaceutical Co ltd · Expires 2020-06-12 · 6y expired

What this patent protects

本发明提供了一种坦西莫司注射用浓溶液的制备方法：主要由活性成分、苯甲醇、羟苯丁酯、有机酸或无机酸、pH调节剂和无水乙醇组成。本发明制得的制剂，有关物质小，在长期的储存过程中稳定，同时克服了由于水的引入引起坦西莫司异构体和有关物质增大的问题。

USPTO Abstract

本发明提供了一种坦西莫司注射用浓溶液的制备方法：主要由活性成分、苯甲醇、羟苯丁酯、有机酸或无机酸、pH调节剂和无水乙醇组成。本发明制得的制剂，有关物质小，在长期的储存过程中稳定，同时克服了由于水的引入引起坦西莫司异构体和有关物质增大的问题。

Drugs covered by this patent

Patent Metadata

Patent number
CN105687132B
Jurisdiction
CN
Classification
—
Expires
2020-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Lunan Better Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.